Acute cholecystitis - an isolated unusual presentation of thrombotic microangiopathy of gall bladder due to antiphospholipid syndrome with lupus positivity detected by [99mTc]Tc-mebrofenin scan

Document Type : Case Report

Authors

Department of Nuclear Medicine and Molecular Imaging, Amrita Institute of Medical Sciences, Cochin, Kerala, India

Abstract

Occurrence of small-vessel occlusions (thrombotic microangiopathy, TMA) in association with antiphospholipid antibodies (aPL ab) has been documented. But isolated involvement of gall bladder due to TMA in secondary aPLS (antiphospholipid syndrome) in post-partum status has been unreported. aPL and systemic lupus erythematosus (SLE) are two closely related diseases that not only share lupus susceptibility genes but can also produce thrombosis. Here we present a young lady, recently delivered with SLE experiencing moderate to severe right abdominal pain and occasional vomiting. A hepatobiliary iminodiacetic acid (HIDA) scan revealed non visualization of gall bladder (GB) confirming the diagnosis of acute acalculous cholecystitis (AAC). Investigations revealed high titre of anti-β2 glycoprotein I (β2GPI) IgG and anti-Cardiolipin (aCL) IgG antibodies confirming aPL syndrome. Antinuclear antibody, double-strand dsDNA was found to be positive confirming SLE. Open cholecystectomy was performed and histology revealed AAC, vasculitis with small vessel ischemia of gallbladder. GB non visualization on HIDA scan (ACC) due to solitary thrombotic microangiopathy of GB is being highlighted in this case of active SLE and secondary aPLS. Early diagnosis is mandatory to avoid repetitive thrombotic occlusions in active cases of SLE with aPLS.

Keywords

Main Subjects

References

  1. Ganpathi IS, Diddapur RK, Eugene H, Karim M. Acute acalculous cholecystitis: challenging the myths. HPB (Oxford). 2007;9(2):131-4.
  2. Treinen C, Lomelin D, Krause C, Goede M, Oleynikov D. Acute acalculous cholecystitis in the critically ill: risk factors and surgical strategies. Langenbecks Arch Surg. 2015;400(4):421-7.
  3. Mazzoccoli C, Comitangelo D, D’Introno A, Mastropierro V, Sabba C, Perrone A. Antiphospholipid syndrome: a case report with an unusual wide spectrum of clinical manifestations. Auto Immun Highlights. 2019 Oct 19;10(1):9. 
  4. McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev. 2020 Jan;39:100610.
  5. Devreese KMJ, Ortel TL, Pengo V, De Laat B. Laboratory criteria for antiphospholipid syndrome: communication from the Ssc of the Isth. J Thromb Haemost. 2018 Apr;16(4):809-813.
  6. Limper M, de Leeuw K, Lely AT. Diagnosing and treating antiphospholipid syndrome: a consensus paper. Neth J Med. 2019 Apr;77(3):98-108.
  7. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117(12):997-1002.
  8. Di Prima FA, Valenti O, Hyseni E, Giorgio E, Faraci M, Renda E. Antiphospholipid Syndrome during pregnancy: the state of the art. J Prenat Med. 2011;5(2):41-53.
  9. Zdrojewski Z. Systemic lupus erythematosus and antiphospholipid syndrome - diagnostic and therapeutic problems. Wiad Lek. 2018;71(1 pt 1):40-46.
  10. Asherson RA, Pierangeli SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66(4):429-432.

Files

Share

How to cite

Statistics